Physician profile
Christopher James Huffman
NPI 1780826651
$20,778.48
in general payments reported to CMS, 2019-2025
23 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,339 · 2020: $1,347 · 2021: $8,607 · 2022: $1,209 · 2023: $5,756 · 2024: $1,343 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,250 · Food and Beverage: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,250.00 |
| Food and Beverage | $2,025.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14,874.05 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $1,060.77 | 2019-2025 | Watchman Access System, General - Vascular Intervention, Avvigo Guidance System |
| Novartis Pharmaceuticals Corporation | $959.55 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $687.80 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $574.26 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $552.24 | 2023-2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $392.08 | 2019-2024 | Farxiga |
| Pfizer INC. | $340.28 | 2019-2023 | |
| Amgen INC. | $267.09 | 2019-2024 | Repatha |
| Irhythm Technologies, INC. | $222.06 | 2019-2020 | |
| Biotronik INC. | $187.34 | 2020-2025 | Biomonitor, Acticor 7 Vr-T Dx |
| Cvrx, INC. | $136.53 | 2023 | Barostim Neo System |
| Medtronic, INC. | $126.84 | 2019-2025 | Aurora Ev-Icd Mri Surescan |
| Merck Sharp & Dohme LLC | $60.44 | 2021 | |
| Amarin Pharma, INC. | $56.62 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $53.37 | 2019-2023 | |
| Abbott Laboratories | $51.61 | 2021 | |
| Astellas Pharma US INC | $47.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.61 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $29.45 | 2019 | |
| Esperion Therapeutics, INC. | $24.55 | 2021 | |
| Alnylam Pharmaceuticals INC. | $23.11 | 2024 | Onpattro |
| Alimera Sciences, INC. | $20.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.